Selected Key Figures

  • Sales

    Key figure Sales (bar chart)Key figure Sales (bar chart) Inactive key figure Sales (bar chart)Inactive key figure Sales (bar chart)
  • EBITDA Before Special Items

    Key figure EBITDA margin (bar chart)Key figure EBITDA margin (bar chart) Inactive key figure EBITDA margin (bar chart)Inactive key figure EBITDA margin (bar chart)
  • Net income

    Inactive key figure Net income (bar chart)Inactive key figure Net income (bar chart) Key figure Net income (bar chart)Key figure Net income (bar chart)


Sales of the Bayer Group increased by 3.5 percent to €11,262 million in the third quarter of 2016 after adjusting for currency and portfolio changes (reported: +2.3 percent).

View all Q3 key figures


Group EBITDA before special items improved by 6.0 percent to €2,682 million.

View all Q3 key figures


After income tax expense of €305 million and income from discontinued operations after income taxes and noncontrolling interest, net income in the third quarter of 2016 came to €1,187 million (Q3 2015: €999 million).

View all Q3 key figures

Business Development of the Divisions


Sales of Pharmaceuticals rose by an encouraging 7.6 percent currency and portfolio adjusted to €4,152 million in the third quarter of 2016. Our recently launched products showed continued strong development.

Find out more

Consumer Health

Sales of Consumer Health rose by 3.6 percent currency and portfolio adjusted in the third quarter of 2016 to €1,425 million. Business developed positively in the Latin America / Africa / Middle East, North America and Asia / Pacific regions.

Find out more

Crop Science

In the third quarter of 2016, Crop Science posted sales of €2,057 million (currency and portfolio adjusted +0.0 percent). Business at Crop Protection / Seeds was steady overall at the prior-year level despite an ongoing weak market environment, particularly in Latin America. Sales of Environmental Science developed very encouragingly.

Find out more